SCHEMBL5489912

SCHEMBL5489912

CCOc1cc(N)c(C(=O)c2ccccc2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
TSHR P16473 1/20 0.51
CASP3 P42574 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
MAPT P10636 4/20 0.50
KDM4E B2RXH2 3/20 0.50
HSD17B10 Q99714 3/20 0.50
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
MAPK1 P28482 2/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
RECQL P46063 1/20 0.50
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ALOX15 P16050 1/20 0.48
POLB P06746 1/20 0.47
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5489041 1.00 LMNA (0.52) LMNATSHRCASP3SENP6MAPT
SCHEMBL4709547 0.94 LMNA (0.57) LMNATSHRMAPTHSD17B10RAB9A
SCHEMBL4707952 0.90 MAPT (0.59) LMNAMAPTKDM4EHSD17B10MAPK1
SCHEMBL5044303 0.83 MAPT (0.50) LMNATSHRMAPTHSD17B10RAB9A
SCHEMBL11593329 0.83 MAPT (0.47) LMNAMAPTKDM4EHSD17B10USP2
SCHEMBL10997246 0.82 LMNA (0.60) LMNATSHRMAPTHSD17B10RAB9A
SCHEMBL24792666 0.81 MAPK1 (0.56) TSHRMAPTKDM4EHSD17B10RAB9A
SCHEMBL7300064 0.81 TSHR (0.62) TSHRMAPTKDM4EHSD17B10RAB9A
SCHEMBL7291805 0.81 TSHR (0.62) TSHRMAPTKDM4EHSD17B10RAB9A
SCHEMBL1942261 0.81 MAPT (0.54) LMNATSHRMAPTKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250410-B2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof VIA PHARMACEUTICALS, INC. (US) 2007-07-31 US disclosed
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof BAY CITY CAPITAL LLC 2004-08-05 US disclosed
EP-1392663-A2 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF NEURO3D (FR) 2004-03-03 EP disclosed
WO-2002098865-A2 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF NEURO3D (FR) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof PDE7A, PDE3B, PDE3A LMNA 1410/4885TSHR 1367/4885CASP3 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.